Because different DPP-4 inhibitors may have differing mechanisms of action through which they affect PD development, we performed a drug-by-drug evaluation in our investigation of PD risk in individuals who were diagnosed as having DM and were prescribed a DPP-4 inhibitor. The gene discussed is DPP4; the disease is Parkinson disease.